Clinical Trial Update: Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing the safety and suitability of dabigatran to inhibit thrombin in patients with scleroderma has completed. The study involved systemic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Scleroderma, Interstitial Lung Disease | Phase 1 | Status: COMPLETED